TF and endometriosis: The reason for targeting TF is based on its over-expression in many types of cancer cells, including solid cancers [1-6,12,25,37] and leukaemia [38-40], and very importantly its selective expression in pathological neovascular endothelial cells in cancer [1,2,4], choroidal neovasculature [7,8] and endometriosis [9] but not on normal VECs [1,2,4,7,8].